Ensysce Biosciences, Inc. SEC filings ENSC
Ensysce Biosciences, Inc. has 547 filings in SEC EDGAR's recent list, going back to Oct 3, 2017. Its latest annual report, Form 10-K, was filed on Mar 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| D | Filing | Aug 20, 2026 | — |
| EFFECT | Filing | Jun 26, 2026 | — |
| EFFECT | Filing | Apr 15, 2026 | — |
| CORRESP | Letter to the SEC | Apr 14, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2026 | — |
| EFFECT | Filing | Dec 11, 2025 | — |
| CORRESP | Letter to the SEC | Dec 9, 2025 | — |
| EFFECT | Filing | May 9, 2025 | — |
| CORRESP | Letter to the SEC | May 9, 2025 | — |
| UPLOAD | Letter from the SEC | May 9, 2025 | — |
| D | Filing | Apr 25, 2025 | — |
| EFFECT | Filing | Apr 24, 2025 | — |
| EFFECT | Filing | Apr 23, 2025 | — |
| CORRESP | Letter to the SEC | Apr 23, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| CORRESP | Letter to the SEC | Apr 22, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 21, 2025 | — |
| D | Filing | Apr 14, 2025 | — |
| EFFECT | Filing | Oct 17, 2024 | — |
| EFFECT | Filing | Oct 15, 2024 | — |
| CORRESP | Letter to the SEC | Oct 15, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2024 | — |
| DEL AM | Filing | Oct 10, 2024 | — |
| D | Filing | Sep 12, 2024 | — |
| EFFECT | Filing | May 1, 2024 | — |
| EFFECT | Filing | Apr 5, 2024 | — |
| CORRESP | Letter to the SEC | Apr 3, 2024 | — |
| D | Filing | Feb 21, 2024 | — |
| UPLOAD | Letter from the SEC | Jan 22, 2024 | — |
| RW | Filing | Nov 30, 2023 | — |
| EFFECT | Filing | Nov 21, 2023 | — |
| CORRESP | Letter to the SEC | Nov 20, 2023 | — |
| UPLOAD | Letter from the SEC | Nov 17, 2023 | — |
| POS EX | Filing | May 17, 2023 | — |
| AW | Filing | May 17, 2023 | — |
| EFFECT | Filing | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 9, 2023 | — |
| CORRESP | Letter to the SEC | May 9, 2023 | — |
| UPLOAD | Letter from the SEC | May 4, 2023 | — |
| 8-A12G/A | Filing | Mar 31, 2023 | — |
| D | Filing | Mar 1, 2023 | — |
| 8-A12G/A | Filing | Feb 7, 2023 | — |
| 8-A12G | Filing | Feb 1, 2023 | — |
| EFFECT | Filing | Jan 17, 2023 | — |
| CORRESP | Letter to the SEC | Jan 13, 2023 | — |
| UPLOAD | Letter from the SEC | Jan 13, 2023 | — |
| EFFECT | Filing | Dec 29, 2022 | — |
| CORRESP | Letter to the SEC | Dec 27, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 23, 2022 | — |
| POS EX | Filing | Dec 8, 2022 | — |
| EFFECT | Filing | Dec 6, 2022 | — |
| CORRESP | Letter to the SEC | Dec 6, 2022 | — |
| CORRESP | Letter to the SEC | Dec 6, 2022 | — |
| CORRESP | Letter to the SEC | Nov 16, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 14, 2022 | — |
| EFFECT | Filing | Aug 30, 2022 | — |
| CORRESP | Letter to the SEC | Aug 26, 2022 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2022 | — |
| EFFECT | Filing | Aug 4, 2022 | — |
| CORRESP | Letter to the SEC | Aug 2, 2022 | — |
| UPLOAD | Letter from the SEC | Jul 28, 2022 | — |
| D | Filing | Jul 8, 2022 | — |
| EFFECT | Filing | Nov 3, 2021 | — |
| CORRESP | Letter to the SEC | Nov 1, 2021 | — |
| UPLOAD | Letter from the SEC | Oct 29, 2021 | — |
| D | Filing | Oct 6, 2021 | — |
| EFFECT | Filing | Sep 23, 2021 | — |
| CORRESP | Letter to the SEC | Sep 21, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2021 | — |
| EFFECT | Filing | Jun 16, 2021 | — |
| SEC STAFF LETTER | Filing | Jun 16, 2021 | — |
| CORRESP | Letter to the SEC | Jun 15, 2021 | — |
| CORRESP | Letter to the SEC | Jun 14, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 11, 2021 | — |
| 425 | Filing | Jun 11, 2021 | — |
| 425 | Filing | Jun 1, 2021 | — |
| 425 | Filing | May 18, 2021 | — |
| NT 10-Q | Filing | May 17, 2021 | Mar 31, 2021 |
| 425 | Filing | May 7, 2021 | — |
| CORRESP | Letter to the SEC | May 3, 2021 | — |
| 425 | Filing | Apr 29, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 27, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 22, 2021 | — |
| CORRESP | Letter to the SEC | Apr 16, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2021 | — |
| 425 | Current report | Feb 18, 2021 | — |
| 425 | Current report | Feb 4, 2021 | — |
| 425 | Current report | Feb 3, 2021 | — |
| 425 | Current report | Feb 2, 2021 | — |
| 425 | Current report | Feb 2, 2021 | — |
| 425 | Current report | Feb 1, 2021 | — |
| UPLOAD | Letter from the SEC | Nov 2, 2020 | — |
| PRER14A | Revised preliminary proxy statement | Oct 30, 2020 | — |
| CORRESP | Letter to the SEC | Oct 29, 2020 | — |
| UPLOAD | Letter from the SEC | Oct 29, 2020 | — |
| 425 | Filing | Feb 19, 2020 | — |
| 425 | Filing | Feb 19, 2020 | — |
| 425 | Filing | Feb 19, 2020 | — |
| 425 | Filing | Feb 11, 2020 | — |
| 425 | Filing | Feb 11, 2020 | — |
| 425 | Filing | Feb 11, 2020 | — |
| 425 | 8-k | Jan 31, 2020 | — |
| 425 | Filing | Jan 27, 2020 | — |
| 425 | Filing | Jan 27, 2020 | — |
| 425 | Current report | Jan 27, 2020 | — |
| 425 | Filing | Jan 9, 2020 | — |
| 425 | Filing | Jan 9, 2020 | — |
| 425 | Current report | Jan 8, 2020 | — |
| 425 | Filing | Jan 8, 2020 | — |
| 425 | Filing | Jan 8, 2020 | — |
| 425 | Current report | Jan 7, 2020 | — |
| 425 | Filing | Jan 6, 2020 | — |
| 425 | Filing | Jan 6, 2020 | — |
| 425 | Current report | Jan 6, 2020 | — |
| 425 | Filing | Dec 31, 2019 | — |
| 425 | Current report | Dec 31, 2019 | — |
| 425 | Filing | Dec 30, 2019 | — |
| 425 | Filing | Dec 30, 2019 | — |
| 425 | Current report | Dec 30, 2019 | — |
| EFFECT | Filing | Dec 1, 2017 | — |
| CORRESP | Letter to the SEC | Dec 1, 2017 | — |
| CORRESP | Letter to the SEC | Dec 1, 2017 | — |
| CERTNAS | Auto-generated paper document | Nov 30, 2017 | — |
| CORRESP | Letter to the SEC | Nov 28, 2017 | — |
| CORRESP | Letter to the SEC | Nov 28, 2017 | — |
| 8-A12B | Filing | Nov 28, 2017 | — |
| CORRESP | Letter to the SEC | Nov 16, 2017 | — |
| UPLOAD | Letter from the SEC | Nov 13, 2017 | — |
| CORRESP | Letter to the SEC | Nov 3, 2017 | — |
| UPLOAD | Letter from the SEC | Oct 27, 2017 | — |
| DRS | Filing | Oct 3, 2017 | — |
Showing 132 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ENSC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- La Jolla, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1716947
- Former names
- Leisure Acquisition Corp. (until Jun 30, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.